natgillin/translations-raw huggingface dataset:
Co-administration of omeprazole (40 mg qd) reduced mean nelfinavir AUC, Cmax and Cmin by 36–39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%.
Istodobna primjena omeprazola (40 mg jedanput na dan) smanjila je srednji AUC, Cmax i Cmin nelfinavira za 36–39%, dok su srednji AUC, Cmax i Cmin farmakološki aktivnog metabolita M8 bili smanjeni za 75-92%.
Co-administration of ONIVYDE+5-FU/LV does not alter the pharmacokinetics of ONIVYDE based on the population pharmacokinetic analysis.
Istodobna primjena ONIVYDE+5-FU/LV ne mijenja farmakokinetiku lijeka ONIVYDE na temelju populacijske farmakokinetičke analize.
Co-administration of oral
Istodobna primjena oralnog
Co-administration of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g) did not affect the oral pharmacokinetics of sildenafil.
Istovremena primjena oralnih kontraceptiva (etinilestradiol 30 µg i levonorgestrel 150 µg) nije utjecala na farmakokinetiku sildenafila nakon peroralne primjene.
Co-administration of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g) did not affect the pharmacokinetics of sildenafil.
Istovremena primjena oralnih kontraceptiva (etinilestradiol 30 µg i levonorgestrel 150 µg) nije utjecala na farmakokinetiku sildenafila.
Co-administration of oral midazolam or
Istodobna primjena peroralnog midazolama ili
Co-administration of oral paliperidone prolonged release tablets at steady-state (12 mg once daily) with divalproex sodium prolonged release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.
Istodobna primjena oralnih paliperidon tableta s produljenim oslobađanjem u stanju dinamičke ravnoteže (12 mg jednom dnevno) s divalproeksnatrij tabletama s produljenim oslobađanjem (500 mg do 2000 mg jednom dnevno) nije utjecala na farmakokinetiku valproata u stanju dinamičke ravnoteže.
Co-administration of other fluoropyrimidines with Teysuno.
Istodobna primjena drugih fluoropirimidina s lijekom Teysuno.
Co-administration of other fluoropyrimidines with Teysuno.
Istodobna primjena drugih fluoropirimidina sa lijekom Teysuno.
Co-administration of oxcarbazepine, phenobarbital, or phenytoin, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Istodobna primjena okskarbazepina, fenobarbitala i fenitoina, koji su svi induktori P-gp-a, moţe smanjiti koncentracije tenofoviralafenamida u plazmi, što moţe dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration of para- aminosalicylic acid and ethionamide may intensify adverse reactions of para-aminosalicylic acid, mainly the gastrointestinal effects, including jaundice, hepatitis, nausea, vomiting, diarrhoea, abdominal pain or anorexia.
Istovremena primjena paraaminosalicilatne kiseline i etionamida može pojačati nuspojave paraaminosalicilatne kiseline, i to uglavnom gastrointestinalne, uključujući žuticu, hepatitis, mučninu, povraćanje, proljev, abdominalnu bol i anoreksiju.
Co-administration of parecoxib and heparin did not affect the pharmacodynamics of heparin (activated partial thromboplastin time) compared to heparin alone.
Istodobna primjena parekoksiba i heparina nije utjecala na farmakodinamiku heparina (aktivirano parcijalno tromboplastinsko vrijeme) u usporedbi sa samo heparinom.
Co-administration of paritaprevir and fosamprenavir/ritonavir is contraindicated due to the expected increase of paritaprevir exposure and the lack of clinical data assessing the magnitude of this increase (see section 4.5).
Istodobna primjena paritaprevira i fosamprenavira/ritonavira kontraindicirana je zbog očekivanog povećanja izloženosti paritapreviru i nedostatka kliničkih podataka na temelju kojih bi se ocijenila veličina tog povećanja (vidjeti dio 4.5).
Co-administration of pazopanib 400 mg once daily with cetuximab 250 mg/m2 and irinotecan 150 mg/m2 resulted in an approximately 20 % increase in systemic exposure to SN-38.
Istodobna primjena pazopaniba 400 mg jednom dnevno s cetuksimabom 250 mg/m2 i irinotekanom 150 mg/m2 rezultirala je približno 20% povećanjem sistemske izloženosti za SN-38.
Co-administration of pazopanib with a CYP3A4, P-gp, and BCRP inhibitor, such as lapatinib, will result in an increase in plasma pazopanib concentrations.
Istovremena primjena pazopaniba s inhibitorima CYP3A4, P-gp i BCRP, poput lapatiniba, rezultirat će povećanjem koncentracije pazopaniba u plazmi.
Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g., itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase pazopanib concentrations.
Istovremena primjena pazopaniba s drugim jakim inhibitorima obitelji CYP3A4 (npr., itrakonazol, klaritromicin, atazanavir, indinavir, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, vorikonazol) može povećati koncentracije pazopaniba.
Co-administration of pazopanib with potent P-gp or BCRP inducers may alter the exposure and distribution of pazopanib, including distribution into the CNS.
Istovremena primjena pazopaniba s potentnim induktorima P-gp ili BCRP-a može utjecati na izloženost i distribuciju pazopaniba, uključujući i distribuciju u SŽS.
Co-administration of pitolisant with paroxetine significantly increases pitolisant mean Cmax and AUC0—72h ratio about 47% and 105%, respectively.
Istodobna primjena pitolizanta s paroksetinom značajno povećava omjer srednje vrijednosti Cmax i AUC0—72h pitolizanta za 47 % i 105 %.
Co-administration of pomalidomide with the strong CYP3A4/5 and P-gp inhibitor ketoconazole, or the strong CYP3A4/5 inducer carbamazepine, had no clinically relevant effect on exposure to pomalidomide.
Istodobna primjena pomalidomida s jakim inhibitorom CYP3A4/5 i P-gp-a ketokonazolom, ili jakim induktorom CYP3A4/5 karbamazepinom, nije imala klinički značajnog učinka na izloženost pomalidomidu.
Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated.
Istodobna primjena posakonazola i terfenadina, astemizola, cisaprida, pimozida, halofantrina ili kinidina je kontraindicirana.
Co-administration of potent P-glycoprotein inhibitors such as cyclosporine, ketoconazole, erythromycin, clarithromycin, verapamil, dronedarone and amiodarone is not recommended (see sections 4.5 and 5.2).
Ne preporučuje se istovremena primjena jakih inhibitora P-glikoproteina kao što su ciklosporin, ketokonazol, eritromicin, klaritromicin, verapamil, dronedaron i amiodaron (vidjeti dijelove 4.5 i 5.2).
Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.
Istodobna primjena pregabalina s oralnim kontraceptivima noretisteronom i/ili etinilestradiolom ne utječe na farmakokinetiku niti jednog od tih lijekova u stanju dinamičke ravnoteže.
co-administration of PREZISTA
lijeka PREZISTA s niskim dozama
co-administration of PREZISTA
primjene PREZISTE s niskom dozom
Co-administration of PREZISTA with these anticoagulants may increase concentrations of the anticoagulant.
Istodobna primjena PREZISTE s ovim antikoagulansima može povećati koncentracije antikoagulansa.
Co-administration of proton pump inhibitor (PPI) esomeprazole (40 mg daily for 6 days) with a single dose of 100 mg cabozantinib to healthy volunteers resulted in no clinically-significant effect on plasma cabozantinib exposure (AUC).
Istodobna primjena inhibitora protonske pumpe (IPP) esomeprazola (40 mg dnevno tijekom 6 dana) s jednokratnom dozom od100 mg kabozantiniba u zdravih dobrovoljaca nije imala klinički značajan učinak na izloženost kabozantinibu u plazmi (AUC).
Co-administration of proton- pump inhibitors had no relevant impact on edoxaban exposure.
Istovremena primjena s inhibitorima protonske pume nije imala značajan utjecaj na izloženost edoksabanu.
Co-administration of quetiapine with indinavir is contraindicated (see section 4.3).
Istodobna primjena kvetiapina i indinavira je kontraindicirana (vidjeti dio 4.3).
Co-administration of REYATAZ with triazolam or orally administered midazolam is contraindicated (see section 4.3), whereas caution should be used with co- administration of REYATAZ and parenteral midazolam.
Istovremena primjena lijeka REYATAZ s triazolamom ili peroralno primijenjenim midazolamom je kontraindicirana (vidjeti dio 4.3), dok je oprez potreban kod istovremene primjene lijeka REYATAZ i parenteralnog midazolama.
Co-administration of REYATAZ/ritonavir and indinavir is not recommended (see section 4.4).
Ne preporučuje se istovremena primjena lijeka REYATAZ/ritonavira i indinavira (vidjeti dio 4.4).
Co-administration of REYATAZ/ritonavir with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate has not been studied, and therefore should be avoided (see section 4.5).
Nije ispitana istovremena primjena lijeka REYATAZ/ritonavira i druge hormonske ili oralne kontracepcije koja sadrži progestagene, osim norgestimata, te se stoga mora izbjegavati (vidjeti dio 4.5).
Co-administration of REYATAZ/ritonavir with proton pump inhibitors is not recommended.
Ne preporučuje se istovremena primjena lijeka REYATAZ/ritonavira i inhibitora protonske pumpe.
Co-administration of rifabutin, a potent CYP3A inducer, may significantly decrease cobicistat plasma concentrations.
Istovremena primjena rifabutina, potentnog induktora enzima CYP3A, može značajno smanjiti koncentracije kobicistata u plazmi.
Co-administration of rifabutin, potent CYP3A inducer, may significantly decrease cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Istovremena primjena rifabutina, snažnog induktora gena CYP3A, može značajno smanjiti koncentracije kobicistata i elvitegravira u plazmi, što može dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration of rifampicin (an inhibitor of Organic Anion Transporting Polypeptide [OATP], a strong inducer of CYP3A and 2C19, and inducer of P-gp and uridine-diphospho- glucuronosyltransferases [UGTs]) was associated with a transient (approximately 2-fold) increase in ambrisentan exposure following initial doses in healthy volunteers.
Istovremena primjena s rifampicinom (inhibitor polipeptida koji transportira organske anione [OATP], snažni induktor CYP3A i 2C19, i induktor P-gp i uridin-difosfo-glukuronoziltransferaze [UGT]) je bila povezana sa prolaznim (približno 2 puta) povećanjem izloženosti ambrisentanu nakon početnih doza kod zdravih dobrovoljaca.
Co-administration of rifampicin with a single 450 mg dose of Tarceva resulted in a mean erlotinib exposure (AUC) of 57.5% of that after a single 150 mg Tarceva dose in the absence of rifampicin treatment.
Istovremeno uzimanje rifampicina s jednom dozom lijeka Tarceva od 450 mg rezultiralo je prosječnom raspoloživosti erlotiniba (AUC) od 57,5% raspoloživosti nakon jedne doze lijeka Tarceva od 150 mg bez rifampicina.
Co-administration of rifampicin with telaprevir
Istodobna primjena rifampicina s telaprevirom
Co-administration of rifampicin, rifabutin, and rifapentine, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Istodobna primjena rifampicina, rifabutina i rifapentina, koji su svi induktori P-gp-a, moţe smanjiti koncentracije tenofoviralafenamida u plazmi, što moţe dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration of rilpivirine and cobicistat is expected to increase the plasma concentration of rilpivirine.
Očekuje se da će istovremena primjena rilpivirina i kobicistata povećati koncentraciju rilpivirina u plazmi.
Co-administration of ritonavir with fosamprenavir increase plasma amprenavir AUC by approximately 2-fold and plasma C,ss by 4- to 6-fold, compared to values obtained when fosamprenavir is administered alone.
Uspoređujući s vrijednostima dobivenim kada se fosamprenavir primjenjuje samostalno, istodobna primjena ritonavira s fosamprenavirom povećava AUC amprenavira u plazmi za oko 2 puta, a vrijednost C,ss u plazmi za 4 do 6 puta.
Co-administration of ritonavir with nevirapine does not lead to clinically relevant changes in the pharmacokinetics of either nevirapine or ritonavir.
Primjena ritonavira istodobno s nevirapinom ne uzrokuje klinički značajne promjene farmakokinetike ni nevirapina ni ritonavira.
Co-administration of rivaroxaban
Istodobna primjena rivaroksabana i
Co-administration of rivaroxaban and Tybost is not recommended.
Ne preporučuje se istovremena primjena rivaroksabana i lijeka Tybost.
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk.
Istodobna primjena rivaroksabana s ketokonazolom (400 mg jedanput na dan) ili ritonavirom (600 mg dvaput na dan) dovela je do porasta srednje vrijednosti AUC rivaroksabana za 2,6 puta / 2,5 puta te do porasta srednje vrijednosti Cmax rivaroksabana za 1,7 puta / 1,6 puta, uz značajno povećanje farmakodinamičkih učinaka, što može dovesti do povećanog rizika od krvarenja.
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk.
Istodobna primjena rivaroksabana s ketokonazolom (400 mg jedanput na dan) ili ritonavirom (600 mg dvaput na dan) dovela je do porasta srednje vrijednosti AUC rivaroksabana za 2,6 puta/ 2,5 puta te do porasta srednje vrijednosti Cmax rivaroksabana za 1,7 puta / 1,6 puta, uz značajno povećanje farmakodinamičkih učinaka, što može dovesti do povećanog rizika od krvarenja.
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50 % decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects.
Istodobna primjena rivaroksabana s jakim induktorom CYP3A4 rifampicinom dovela je do smanjenja srednje vrijednosti AUC rivaroksabana za oko 50 %, uz istodobno slabljenje njegovih farmakodinamičkih učinaka.
Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax, but slightly lower values for Cmax (832 ng/ml) and AUC (782 ng·h/ml).
Istovremena primjena tableta robenakoksiba bez umjetnog okusa s hranom nije uzrokovala odgodu u Tmax ali su zabilježene lagano snižene vrijednosti za Cmax (832 ng/ml) i AUC (782 ng·h/ml).
Co-administration of robenacoxib tablets with one third of the daily food ration produced no change in Tmax (0.5 h), Cmax (1,201 ng/ml) or AUC (1383 ng·h/ml).
Istovremena primjena tableta robenakoksiba s jednom trećinom dnevne porcije hrane nije uzrokovala promjenu u Tmax (0,5 h), Cmax (1201 ng/ml) ili AUC (1383 ng·h/ml).
Co-administration of robenacoxib tablets with the entire daily food ration produced no delay in Tmax (0.5 h), but a lower Cmax (691 ng/ml) and a slightly lower AUC (1,069 ng·h/ml).
Istovremena primjena tableta robenakoksiba s cijelom dnevnom porcijom hrane nije uzrokovala odgodu u Tmax (0,5 h), ali je Cmax (691 ng/ml) bio niži, a AUC (1069 ng·h/ml) nešto niži.
Co-administration of salmeterol and Tybost is not recommended (see section 4.4).
Ne preporučuje se istovremena primjena salmeterola s lijekom Tybost (vidjeti dio 4.4).
Co-administration of salmeterol with cobicistat may result in increased plasma concentrations of salmeterol.
Istovremena primjena salmeterola i kobicistata može za posljedicu imati povećane koncentracije salmeterola u plazmi.
Co-administration of Samsca with other treatments for hyponatraemia, and medications that increase serum sodium concentration, is not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations (see section 4.5).
Ne preporučuje se istodobna primjena Samsce s drugim načinima liječenja hiponatremije i s lijekovima koji povećavaju koncentracije serumskog natrija za vrijeme početnog liječenja ili za druge bolesnike s vrlo niskim početnim koncentracijama serumskog natrija (vidjeti dio 4.5).
Co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre- existing liver disease.
Istodobna primjena sakvinavira i ritonavira dovela je do teških štetnih događaja, uglavnom dijabetičke ketoacidoze i poremećaja jetrene funkcije, osobito u bolesnika s postojećom bolešću jetre.
Co-administration of saquinavir/ritonavir and Atripla is not recommended.
Ne preporučuje se istovremena primjena sakvinavira/ritonavira s Atriplom.
Co-administration of saxagliptin and metformin
Istodobna primjena saksagliptina i metformina
Co-administration of Senshio with fluconazole
Istodobna primjena lijeka Senshio i flukonazola
Co-administration of Senshio with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known, or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.
Istodobnu primjenu lijeka Senshio s jakim/umjerenim inhibitorima CYP3A4 potrebno je izbjegavati u bolesnica za koje je poznato ili se sumnja da slabo metaboliziraju CYP2C9 na temelju genotipizacije ili ranijih podataka iz anamneze/iskustava s drugim supstratima CYP2C9.
Co-administration of simeprevir with Atripla is not recommended.
Ne preporučuje se istovremena primjena simeprevira s Atriplom.
Co-administration of simvastatin or lovastatin with REYATAZ is contraindicated due to an increased risk of myopathy including rhabdomyolysis. (see section 4.3).
Kontraindicirana je istovremena primjena simvastatina ili lovastatina s lijekom REYATAZ zbog povišenog rizika od miopatije uključujući rabdomiolizu (vidjeti dio 4.3).
Co-administration of single doses of the P-gp inhibitor cyclosporine A and fidaxomicin in healthy volunteers, resulted in a 4- and 2-fold increase in fidaxomicin Cmax and AUC, respectively and in a 9.5 and 4-fold increase in Cmax and AUC, respectively, of the main active metabolite OP-1118.
Istovremena primjena jednokratnih doza inhibitora P-gp-a ciklosporina A i fidaksomicina u zdravih dobrovoljaca rezultirala je četverostrukim povećanjem Cmax i dvostrukim povećanjem AUC-a fidaksomicina te povećanjem Cmax glavnog djelatnog metabolita OP- 1118 za 9,5 puta i AUC-a za 4 puta.
Co-administration of single or multiple doses of dexamethasone (40 mg/ day) has no clinically relevant effect on the multiple dose pharmacokinetics of lenalidomide (25 mg/ day).
Istodobna primjena pojedinačne doze ili ponovljenih doza deksametazona (40 mg/dan) nije imala klinički značajan učinak na farmakokinetiku ponovljenih doza lenalidomida (25 mg/dan).
Co-administration of sirolimus (2 mg single dose) with multiple-dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 100 mg every 12 hours for 8 days) in healthy subjects has been reported to increase sirolimus Cmax and AUC by an average of 7-fold and 11-fold, respectively.
Opisano je da istodobna primjena sirolimusa (jednokratna doza od 2 mg) s višekratnim dozama peroralnog vorikonazola (400 mg svakih 12 sati tijekom 1 dana, a potom 100 mg svakih 12 sati tijekom 8 dana) u zdravih osoba dovodi do porasta Cmax sirolimusa za prosječno 7 puta, a AUC za 11 puta.
Co-administration of sirolimus and voriconazole is not recommended (see section 4.4).
Ne preporučuje se istodobno davanje sirolimusa i vorikonazola (vidjeti dio 4.4).
Co-administration of sirolimus and voriconazole is not recommended (see section 4.4).
Ne preporučuje se istodobno primjena sirolimusa i vorikonazola (vidjeti dio 4.4).
Co-administration of sirolimus with strong inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin, rifabutin) is not recommended (see section 4.5).
Ne preporučuje se istodobna primjena sirolimusa s jakim inhibitorima enzima CYP3A4 (kao što su ketokonazol, vorikonazol, itrakonazol, telitromicin ili klaritromicin) ili induktorima enzima CYP3A4 (kao što su rifampicin, rifabutin) (vidjeti dio 4.5).
Co-administration of sirolimus with strong inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin, rifabutin) is not recommended (see section 4.5).
Ne preporučuje se istodobna primjena sirolimusa s jakim inhibitorima enzima CYP3A4 (kao što su ketokonazol, vorikonazol, itrakonazol, telitromicin ili klaritromicin) ili induktorima enzima CYP3A4 (kao što su rifampin, rifabutin) (vidjeti dio 4.5).
Co-administration of sirolimus with strong inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin, rifabutin) is not recommended (see section 4.5).
Ne preporučuje se istodobna primjena sirolimusa s jakim inhibitorima enzima CYP3A4 (kao što su ketokonazol, vorikonazol, itrakonazol, telitromicin ili klaritromicin) ili induktorima enzima CYP3A4 (poput rifampicin, rifabutin) (vidjeti dio 4.5).
Co-administration of Sonata together with inducers of CYP3A4 such as rifampicin, carbamazepine and phenobarbitone, may result in a reduction of zaleplon’s efficacy.
Istodobna primjena Sonate zajedno s induktorima CYP3A4, poput rifampicina, karbamazepina i fenobarbitona može rezultirati smanjenjem djelotvornosti zaleplona.
Co-administration of Sonata with a single 800 mg dose of erythromycin, a strong, selective CYP3A4 inhibitor, produced a 34% increase in zaleplon’s plasma concentrations.
Istodobna primjena Sonate s jednokratnom dozom eritromicina od 800 mg, jakog, selektivnog inhibitora CYP3A4, uzrokovala je povećanje koncentracije zaleplona u plazmi za 34%.
Co-administration of Sonata with medicinal products known to influence CYP3A4 is expected to result in changes in zaleplon’s plasma concentrations. (See section 4.5).
Istodobna primjena Sonate i lijekova za koje je poznato da utječu na CYP3A4 može rezultirati promjenama koncentracije zaleplona u plazmi (vidjeti dio 4.5).
Co-administration of Sovaldi with medicinal products that inhibit P-gp and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma concentration, thus Sovaldi may be co-administered with P-gp and/or BCRP inhibitors.
Istodobna primjena Sovaldija s lijekovima koji inhibiraju P-gp i/ili BCRP može povećati koncentraciju sofosbuvira u plazmi bez povećavanja koncentracije GS-331007 u plazmi pa se stoga Sovaldi može istodobno primjenjivati s inhibitorima P-gp i/ili BCRP.
Co-administration of St. John’s wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Istodobna primjena gospine trave, induktora P-gp-a, moţe smanjiti koncentracije tenofoviralafenamida u plazmi, što moţe dovesti do gubitka terapijskog učinka i razvoja rezistencije.
Co-administration of Stribild and lovastatin and simvastatin is contraindicated (see section 4.3).
Istovremena primjena Stribilda i lovastatina i simvastatina je kontraindicirana (vidjeti dio 4.3).
Co-administration of Stribild and orally administered midazolam and triazolam is contraindicated (see section 4.3).
Istovremena primjena Stribilda i midazolama koji je primijenjen peroralno i triazolama je kontraindicirana (vidjeti dio 4.3).
Co-administration of Stribild and other medicinal products primarily metabolised by CYP3A such as amiodarone, quinidine, cisapride, pimozide, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see section 4.3).
Kontraindicirana je i istovremena primjena Stribilda i drugih lijekova koje prvenstveno metabolizira CYP3A, kao što su amiodaron, kinidin, cisaprid, pimozid, alfuzosin i sildenafil za plućnu arterijsku hipertenziju (vidjeti dio 4.3).